SG10202111892XA - Methods for treating dravet syndrome - Google Patents
Methods for treating dravet syndromeInfo
- Publication number
- SG10202111892XA SG10202111892XA SG10202111892XA SG10202111892XA SG10202111892XA SG 10202111892X A SG10202111892X A SG 10202111892XA SG 10202111892X A SG10202111892X A SG 10202111892XA SG 10202111892X A SG10202111892X A SG 10202111892XA SG 10202111892X A SG10202111892X A SG 10202111892XA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- dravet syndrome
- treating dravet
- treating
- syndrome
- Prior art date
Links
- 201000007547 Dravet syndrome Diseases 0.000 title 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 title 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762490357P | 2017-04-26 | 2017-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202111892XA true SG10202111892XA (en) | 2021-12-30 |
Family
ID=63920144
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111892XA SG10202111892XA (en) | 2017-04-26 | 2018-04-26 | Methods for treating dravet syndrome |
| SG11201909963Y SG11201909963YA (en) | 2017-04-26 | 2018-04-26 | Methods for treating dravet syndrome |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909963Y SG11201909963YA (en) | 2017-04-26 | 2018-04-26 | Methods for treating dravet syndrome |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200163943A1 (en) |
| EP (1) | EP3615010A4 (en) |
| JP (1) | JP7326159B2 (en) |
| KR (1) | KR102616994B1 (en) |
| CN (1) | CN110799215A (en) |
| AU (1) | AU2018260693B2 (en) |
| CA (1) | CA3061712A1 (en) |
| IL (1) | IL270137B2 (en) |
| RU (1) | RU2767661C2 (en) |
| SG (2) | SG10202111892XA (en) |
| WO (1) | WO2018200844A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6957460B2 (en) | 2015-10-22 | 2021-11-02 | カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． | How to Treat Angelman Syndrome and Related Disorders |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (en) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN110545806A (en) | 2017-02-15 | 2019-12-06 | 卡维昂公司 | calcium channel inhibitors |
| IL270180B (en) | 2017-04-26 | 2022-06-01 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders |
| EP3860571A4 (en) | 2018-10-03 | 2022-06-29 | Cavion, Inc. | Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide |
| WO2020178695A1 (en) | 2019-03-01 | 2020-09-10 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| CN112353767A (en) * | 2020-11-16 | 2021-02-12 | 海南锦瑞制药有限公司 | Diltiazem hydrochloride and pregabalin composition, and preparation method and application thereof |
| WO2022132691A1 (en) * | 2020-12-16 | 2022-06-23 | Caamtech, Inc. | Amanita muscaria compounds |
| EP4346817A1 (en) * | 2021-05-24 | 2024-04-10 | Cavion, Inc. | Method of treating essential tremor |
| AU2022329834A1 (en) | 2021-08-17 | 2024-03-07 | Korea Advanced Institute Of Science And Technology | Antisense oligonucleotide targeting cav3.1 gene and uses thereof |
| IT202100023651A1 (en) * | 2021-09-14 | 2023-03-14 | Edilio Lancellotti | Niaprazine for veterinary use in the treatment of disorders of the central nervous system |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008144571A (en) | 2006-04-12 | 2010-05-20 | Мерк энд Ко., Инк. (US) | Pyridylamide antagonists of Calcium channels of T-type |
| US8377968B2 (en) * | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| WO2011093393A1 (en) * | 2010-01-29 | 2011-08-04 | 国立大学法人岡山大学 | Method for assessment of potential for development of dravet syndrome and use thereof |
| WO2012094615A2 (en) * | 2011-01-07 | 2012-07-12 | Zenyaku Kogyo Kabushikikaisha | Use of cav3.1 selective t-type calcium channel antagonists |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US9351968B1 (en) * | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| JP6957460B2 (en) * | 2015-10-22 | 2021-11-02 | カビオン・インコーポレイテッドＣａｖｉｏｎ， Ｉｎｃ． | How to Treat Angelman Syndrome and Related Disorders |
-
2018
- 2018-04-26 RU RU2019137951A patent/RU2767661C2/en active
- 2018-04-26 CN CN201880040389.9A patent/CN110799215A/en active Pending
- 2018-04-26 IL IL270137A patent/IL270137B2/en unknown
- 2018-04-26 WO PCT/US2018/029610 patent/WO2018200844A1/en unknown
- 2018-04-26 KR KR1020197034824A patent/KR102616994B1/en active IP Right Grant
- 2018-04-26 SG SG10202111892XA patent/SG10202111892XA/en unknown
- 2018-04-26 AU AU2018260693A patent/AU2018260693B2/en active Active
- 2018-04-26 SG SG11201909963Y patent/SG11201909963YA/en unknown
- 2018-04-26 EP EP18791035.1A patent/EP3615010A4/en active Pending
- 2018-04-26 US US16/608,355 patent/US20200163943A1/en not_active Abandoned
- 2018-04-26 JP JP2019558464A patent/JP7326159B2/en active Active
- 2018-04-26 CA CA3061712A patent/CA3061712A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018260693B2 (en) | 2024-01-11 |
| CN110799215A (en) | 2020-02-14 |
| KR20190139302A (en) | 2019-12-17 |
| RU2019137951A (en) | 2021-05-26 |
| EP3615010A4 (en) | 2021-06-30 |
| CA3061712A1 (en) | 2018-11-01 |
| IL270137B2 (en) | 2024-04-01 |
| EP3615010A1 (en) | 2020-03-04 |
| AU2018260693A1 (en) | 2019-11-14 |
| JP7326159B2 (en) | 2023-08-15 |
| RU2767661C2 (en) | 2022-03-18 |
| US20200163943A1 (en) | 2020-05-28 |
| KR102616994B1 (en) | 2023-12-26 |
| IL270137A (en) | 2019-12-31 |
| RU2019137951A3 (en) | 2021-08-20 |
| IL270137B1 (en) | 2023-12-01 |
| WO2018200844A1 (en) | 2018-11-01 |
| SG11201909963YA (en) | 2019-11-28 |
| JP2020517708A (en) | 2020-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202111892XA (en) | Methods for treating dravet syndrome | |
| SI3785717T1 (en) | Methods for treating coronaviridae infections | |
| EP3500289A4 (en) | Methods for treating tracheobronchomalacia | |
| EP3299697C0 (en) | Dehumidifying apparatus | |
| HK1244217A1 (en) | Methods for treating proteinopathies | |
| HK1245804A1 (en) | Anti-csf1r antibodies for treating pvns | |
| IL251108A0 (en) | Compositions and methods for treating acute radiation syndrome | |
| GB201502964D0 (en) | Apparatus for treating gas | |
| HK1255481A1 (en) | Methods for treating hcv | |
| IL259856A (en) | Composition for treatment of crigler-najjar syndrome | |
| HK1232291A1 (en) | Substrates and methods for collection, stabilization and elution of biomolecules | |
| EP3442538A4 (en) | Treating extrapyramidal syndrome using trapidil | |
| HK1248133A1 (en) | Methods for treating neuroblastoma | |
| HUE061051T2 (en) | Tasimelteon for treating smith-magenis syndrome | |
| EP3338618A4 (en) | Method for washing treatment tool-raising base | |
| SG11202003127WA (en) | Methods for treating lymphomas | |
| HK1258054A1 (en) | Methods and compositions for treating hunter syndrome | |
| SG11201911553VA (en) | Adsorption method | |
| IL254336A0 (en) | Novel treatment method | |
| ZA201607068B (en) | Methods for treating hypersomnia | |
| PT3250218T (en) | Methods for treating obesity | |
| GB2561308B (en) | Dehumidification apparatus | |
| PL3754845T3 (en) | Apparatus for absorbing electrical noise | |
| GB201802348D0 (en) | Gas treating apparatus | |
| ZA202000943B (en) | Methods for treating hcv |